icon-folder.gif   Conference Reports for NATAP  
 
  AASLD
61th Annual Meeting of the American Association for the Study of Liver Diseases
Boston, MA, Hynes Convention Center
October 30-November 3, 2010
Back grey_arrow_rt.gif
 
 
 
No Resistance to Tenofovir Disoproxil Fumarate (TDF) Detected Following up to 192 Weeks of Treatment in Subjects Mono-Infected with Chronic Hepatitis B Virus
 
 
  Reported by Jules Levin
AASLD Nov 1 2010 Boston
 
AASLD: Long Term (4 Year) Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) Treatment in HBeAg-Positive Patients (HBeAg+) with Chronic Hepatitis B (Study 103) - (11/04/10)
 
AASLD: Continued Efficacy and Safety Through 4 Years of Tenofovir Disoproxil Fumarate (TDF) Treatment in HBeAg-Negative Patients with Chronic Hepatitis B (Study 102) - (11/04/10)
 
A Snow-Lampart1, K Kitrinos1, B Chappell1, F Myrick1, J Schawalder1, E J Heathcote2, P Marcellin3, and K Borroto-Esoda1 1Gilead Sciences, NC, USA; 2Toronto General Hospital, Ontario, Canada; 3Hospital Beaujon, Clichy, France